Expert Consensus on the Combined Application of Radiotherapy and Novel Systemic Agents in Breast Cancer Treatment.

J Evid Based Med · 2026 · PMC13320105 · PMID 42347760

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Advanced BC: Bevacizumab The strongest evidence for Bevacizumab comes from brain metastases: the BEEP trial showed a trend toward improved brain‐specific PFS with WBRT plus induction Bevacizumab versus WBRT alone [ 87 ]; the Phase I REBECA study also found Bevacizumab plus WBRT to be well tolerated [ 88 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.